Webinar
The New Era of MRD: Redefining the Standard in Ultra-sensitive Detection

Israeli Dx Firm JaxBio Looks to Broaden Access to DNA Methylation-Based Liquid Biopsy Testing

Jul 13, 2026 | Justin Petrone

Premium | Save for later

NEW YORK – Israel-diagnostics firm JaxBio is aiming to make DNA methylation-based cancer diagnostics more widely available by advancing its fluorescence-based platform for the early detection and therapeutic monitoring of multiple cancer types, starting with lung.

To that end, the Tel Aviv-based company and its partners recently published a proof-of-concept study showcasing the ability of its technology, which is based on the fluorescent enzymatic profiling of cell-free DNA methylation, to detect lung cancer in samples from a retrospective cohort of 1,000 patients. The study was being presented collaborators in Europe and the US with the intention of commercializing its assays in these regions, and eyeing other indications such as hematological cancers.

According to CEO Shahar Ziknin, JaxBio sees its lower-cost, lower-complexity approach as a complement to computed tomography (CT) scans and potentially competing with approaching based methylation profiling tests focused on lung cancer, such as Delfi Diagnostics' FirstLook Lung liquid biopsy assay, or multicancer early detection tests offered by Grail and Nalasens.

For the study, published in June in NPJ Precision Oncology, JaxBio and collaborators at Tel Aviv University, Bnai Zion Medical Center and Technion in Haifa, Cisam Sheba Medical Center in Ramen Gat, and Bar Ilan University in Nazareth, used JaxBio's platform to look at 103 patients with available preoperative blood plasma samples — 41 cases and 62 controls — and 897 cancer-free controls. JaxBio's platform could be run on an in-house developed data-analysis pipeline, was able to detect lung cancer in samples from those with lung cancer with 93.1 percent sensitivity at 90.3 percent specificity.

The authors also reported that they achieved these results with a turnaround time of two or three days and at an estimated cost of about $60 per sample. The company said that its assay takes less a turnaround time of 10-14 days with a reported cost of several hundred dollars, though the company does not advertise a price publicly. Meanwhile, Grail's Galleri test costs $949 for self-pay and has a turnaround time of about two weeks, according to its website.

For its study, JaxBio used Agilent 60K Human CGH microarrays, but Ziknin said that JaxBio "hasn't locked in" any specific platform for its tests, and is in touch with different manufacturers. However, the lower cost and workflow complexity of its approach compared to next-generation sequencing-based assays means the company can "bring liquid biopsy testing closer to the point of care," and "democratize access to personalized oncology for low-income, underserved, and rural populations," Ziknin said. Its platform's capabilities are supported by AI-driven models that improve signal interpretation and filter out noise.

The test could be used not only to diagnose patients, but monitored, but also for early recurrence detection and monitoring, leading to more timely treatment decisions. Ziknin said that in the case of lung cancer, people at higher risk of developing the disease often have to undergo multiple scans, though they are encouraged to undergo them annually. He said that there are about 1.5 million people at risk in the US, where as many as 15 million people are eligible per year for CT-based lung cancer screening, administered as part of routine care.

The company is now looking at the matrix tests available beyond tissue, with its population of interest in the US being those who are undergoing clinical trials. Dine that focused on lung cancer, called Lumen (also the test's name), commenced in November 2024 and is supported through a $2 million European Innovation Council Accelerator grant. A second trial called Sangyne started in January 2023 and is focused on hematological cancers, backed by $5.5 million in Horizon Europe funding. Both studies are expected to wrap up later this year.

According to Ziknin, JaxBio currently has 14 employees and has raised about $10 million in seed funding since it began the Sangyne trial in 2020. With the EIC support, he said the company is developing the Lumen test, including the reagents, software, and workflow, and is preparing for a fully validated pilot by the Sangyne trial. In the meantime, has produced a tool called HemaCrisp, which is capable of detecting hematologic malignancy and precancerous conditions.

"The chip is now being deployed in several hospitals, side by side with standard of care," said Ziknin.

The company's next step will be to bring these tests to market in the US and Europe, initially via partners in laboratory-developed tests, while progressing towards meeting US Food and Drug Administration requirements for a kit. Ziknin said that JaxBio has had commercial discussions with Grail, but that Ziknin is targeting a US launch by the end of 2027 but "the exact timing will depend on the progress of the clinical validation, regulatory discussions and solution partner selection."

A launch within Israel would likely happen at the same time, or even earlier, Ziknin said, noting that JaxBio is "in close communication" with the Israeli Ministry of Health.

Filed Under: Cancer, Molecular Diagnostics, Liquid Biopsy, Middle East, Hybridization, Microarrays & Multiplexing, PCR, methylation, Lung Cancer, hematologic malignancies, Editor's Pick

We recommend

Angle Looks to Dual CTC, cfDNA Analysis, Illumina Tie-up to Expand Cancer Dx, CDs Business
Expand Rep, Genomeweb, 2026

Israeli Liquid Biopsy Startup Senseera Raises $7.1M in Seed Round
Reuters

PanGia Biotech Preparing Urine-Based Prostate Cancer Test for Commercialization
Kerry Robertson, BioDx, 2026

Korea's MBDx Explores NSCLC Therapy Guidance, Multi-Cancer Early Detection Tests from Seed Round
Kristen Fox, BioDx, 2026

In Brief This Week: Oncoplex, Elsan, Biogen, Roche, Gilead, CSL, Behring, Pfizer
Precision Medicine Online, 2026

Powered by TREND ETC

Breaking News

- OncBura Withdrawal of FDA Submission for CT-NIG Molecular Test Raises Shortcut Bio Milestone Payments
- Newly Discovered 'PCR Leaping' Artifact Could be Useful for Bacterial Gene Screening
- AI-Based Histology Analysis Leads to Tissue-Specific Aging Clocks, Transcriptomic Profiles in Blood
- Prototype Diagnostics Initiates New Study of MCED Test to Support CE-IVDR Submission
- In Brief This Week: Bio-Techne, Interpace, MDxHealth, IMDx, Bionano Genomics, Revvity, More

FOUNDATION MEDICINE
On-Demand Webinar
The New Era of MRD: Redefining the Standard in Ultra-sensitive Detection
View now

FOUNDATION MEDICINE
On-Demand Webinar
The New Era of MRD: Redefining the Standard in Ultra-sensitive Detection
View now

What's Popular?

1. Newly Discovered 'PCR Leaping' Artifact Could be Useful for Bacterial Gene Screening
2. Newborn Genetic Screening Shows Potential for Identifying Children at Risk for Early Cancers
3. OncBura Withdrawal of FDA Submission for CT-NIG Molecular Test Raises Shortcut Bio Milestone Payments
4. AI-Based Histology Analysis Leads to Tissue-Specific Aging Clocks, Transcriptomic Profiles in Blood
5. Prototype Diagnostics Initiates New Study of MCED Test to Support CE-IVDR Submission

FOUNDATION MEDICINE
On-Demand Webinar
The New Era of MRD: Redefining the Standard in Ultra-sensitive Detection
View now

Sponsorships

Privacy Policy, Terms & Conditions, Copyright © 2026 GenomeWeb, a new name in the Clarivate Communications. All Rights Reserved.